Cellular tumor suppressors p53 and Rb play an important role in controlling cell proliferation. Inactivation of these tumor suppressor proteins can occur by gene mutation or by asiation with oncoproteins from the small DNA tumor viruses. One function of p53 is in regulating cell cycle checkpoint control after DNA damage. To dissect the pathways by which p53 and Rb may act, the E6 and E7 oncogenes of human papillomavirus (HPV) types 6 and 16 were introduced into primary human epitheial cells by retroviral transfer vector, and cells were assayed for growth arrest after DNA damage induced by actinomycin D. The E6 or E7 oncogenes from the low-risk HPV6 had no affect on growth arrest, p53 protein levels increased, Rb protein levels decremd, and Rb was predominantly in the hypophosphorylated state similar to vector-infected cells. Either the E6 or the E7 oncogene from the high-risk HPV16 abrogated growth arrest. Cells expressing HPV16 E6 (16E6) were severely-reduced in p53 protein levels that did not increase detectably after DNA damage, Rb protein levels did not decrease, and hyperphosphorylated Rb was present. After DNA damage in cells expressing 16E7 p53 levels increased, and Rb protein levels decreased; however, Rb was predominantly in the hyperphosphorylated state. Even though p53 protein levels increased in response to DNA damage in cells expressing 16E7, G, growth arrest was bypassed. This suggests that the circuitry controlling the growth arrest signal after DNA damage may be interconnected between the p53 and Rb pathways.
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The link between tumor suppressor proteins and cell cycle control is not clear. The subsequent inactivation of the wild-type p53 or RBI gene in patients that carry mutant and wild-type alleles in the germ line is responsible for the inherited cancer susceptibility syndromes in humans LiFraumeni and retinoblastoma, respectively (1) . Mice engineered to be lacking the p53 gene developed normally but had a predisposition for tumor formation, indicating that cell divisions and complete normal development occurred in the absence of p53 (2) . Mice generated without Rb developed up to days 12-14 in embryogenesis, suggesting that, as in the case of p53, cell divisions can occur normally in the absence of Rb; however, Rb apparently was required for some cells of the neuronal and erythropoietic lineages to differentiate normally (3) (4) (5) .
The mechanism by which Rb is able to control cell proliferation at the cell cycle level is thought to involve binding and release of E2F, a transcriptional activator, due to cyclic phosphorylation and dephosphorylation events of Rb during the cell cycle (reviewed in ref. 6) . Rb is underphosphorylated early in G1, binding to E2F, and becomes heavily phosphorylated at the transition of G1 to S, thereby releasing free E2F. E2F binding sites on the dihydrofolate reductase promoter are responsible for up-regulation of transcription at the G1/S boundary for this S-phase gene (7) . Cyclin/cdk complexes have been implicated in controlling the phosphorylation events of Rb and the ability to relieve Rb suppression of growth (8, 9) , thus connecting a tumor suppressor gene with the cell cycle.
One way that p53 may act as a tumor suppressor is in controlling a G1 checkpoint after DNA damage (10) . Upon DNA damage, cells growth arrest in G1 and G2. p53 has been shown to mediate G1 growth arrest in that cells with mutated or no p53 do not growth arrest in G1 after DNA damage (11) . G2 arrest is not affected in cells with mutated p53. Cells with no p53 can undergo gene amplification (12) , further suggesting a role for p53 in maintaining genomic stability.
The inactivation of cellular tumor suppressor proteins p53 and Rb by association with viral oncoproteins is a mechanism shared among the small DNA tumor viruses simian virus 40 (SV40) (13, 14) , adenovirus (15, 16) , and human papillomavirus (HPV). HPV has been identified as an etiologic agent in anogenital cancers (17). Only a particular subset of HPVs, such as types 16 and 18 , that infect the anogenital tract are associated with high risk of malignant conversion (18) . Other types, such as 6 and 11, are associated with benign genital warts and are at low risk for malignant conversion. The introduction of E6 and E7 genes from high-risk types is sufficient for efficient immortalization of primary human keratinocytes (19) (20) (21) . E7 binds to the tumor suppressor Rb (22) and related proteins such as p107 and p130 (23) and is the dominant oncogene since rare colonies can become immortalized that harbor only E7 (21, 24) . The E6 protein binds to the cellular tumor suppressor p53 (25) and targets p53 for degradation via the ubiquitin proteolysis pathway (26) . In addition, it has been shown that HPV16 E6 (16E6) is able to abrogate growth arrest induced by DNA damage, presumably due to degradation of the p53 protein mediated by 16E6 (27) .
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Radloimmunoprecipitations. Cells were labeled for 2 h with 200 ,uCi of [35S]cysteine and 100 ,uCi of 35S express label (Amersham) per 100-mm plate (1 Ci = 37 GBq). Rabbit polyclonal antisera generated against HPV6 and -16 E6 and E7 bacterial fusion proteins (29) was used to immunoprecipitate the HPV proteins. Radioimmunoprecipitations were done as described (30) .
Growth Arrest. DNA damage was induced by treating the cells for 24 h with 0.5 nM actinomycin D (31, 32) . Cells were prepared for flow cytometry analysis as described (33) 
RESULTS
Primary human foreskin epithelial cells (HFEs) were infected with retroviruses expressing the E6 and E7 oncogenes from HPV6 and -16, selected for neomycin resistance, and immediately assayed for growth arrest after DNA damage induced by actinomycin D. Therefore, the effects ofthe oncogenes on growth arrest after DNA damage were assessed in the absence of further cellular events that might have occurred during prolonged passage or crisis in culture. At low concentrations, actinomycin D induces DNA breaks similar to ionizing radiation by inhibiting cellular topoisomerases (31, 32) and has been shown to cause G1 arrest (10, 34) with actinomycin D for 24 h. Fig. 3 shows that the p53 protein levels were increased 2-to 10-fold upon actinomycin D treatment in all cells, except those expressing 16E6. The levels ofp53 were extremely low in cells expressing 16E6 and longer exposures did not reveal any increase in p53 protein after exposure to actinomycin. We had previously noted that p53 protein levels were elevated in cells expressing the 16E7 oncoprotein (35) , and in this experiment a 2-to 5-fold increase in p53 protein levels was observed in cells expressing 16E7 compared to vector, 6E6, or 6E7 cells. A further 2-fold elevation in p53 protein was observed after treatment; thus, the ability to stabilize the p53 protein upon actinomycin D treatment was not impaired in the 16E7-expressing HFEs. Nonetheless, the cells did not growth arrest after DNA damage.
Rb Protein Levels and Phosphorylation. Since 16E7 was able to abrogate growth arrest and 16E7 associates with the Rb tumor suppressor protein (22) , Western blot analysis of Rb protein in untreated cells and in cells after DNA damage was performed. The Rb tumor suppressor has multiple phosphorylated forms that run with various mobilities on SDS/ PAGE (36) . The fastest-migrating form is the hypophosphorylated form that appears in the cell after mitosis and becomes phosphorylated at the transit from G1 to S. It is the underphosphorylated form that is thought to act in limiting cell proliferation and is the form that binds viral oncoproteins SV40 large tumor antigen and papillomavirus 16E7 (36, 37) . Fig. 4 shows that the Rb protein levels dropped upon actinomycin D treatment, except in cells expressing 16E6. Rb levels had previously been shown to decrease due to type ,B transforming growth factor-induced growth arrest in epithelial cells (38) 
DISCUSSION
We have shown that expression of either the 16E6 or the 16E7 gene in primary human epithelial cells was able to abrogate G1 arrest after DNA damage. The oncoproteins from the low-risk HPV6 had no effect on growth arrest. It has been previously shown that 16E6 was able to disrupt the ability of p53 to modulate transcription (39, 40) and to arrest in G1 after DNA damage (27) . Because each of the small DNA tumor viruses produces oncoproteins that interact with the cellular tumor suppressors p53 and Rb, it has been suggested that cells have two independent pathways controlling cell proliferation and that both the p53 and Rb pathways must be inactivated in order to bring about the transformed phenotype. Expression of 16E7 in epithelial cells was able abrogate growth arrest, which has been shown to be mediated by p53; thus, the p53 and Rb pathways may be interconnected for at least some aspects ofgrowth control. (46) . Either after type (3 transforming growth factor treatment ofcells expressing SV40 large tumor antigen (38) or after DNA damage of cells expressing 16E7 Rb does not remain hypophosphorylated. There are two possible explanations for the observation ofphosphorylated Rb. One is that the free E2F has driven the cell into S phase and as a result Rb has become phosphorylated. Another is that the Rb must become phosphorylated for the cell to pass through the restriction point. The second model implies that in addition to binding Rb, viral oncoproteins may supply further activities in order to inactivate the antiproliferative properties of tumor suppressor proteins.
Ela proteins with mutations that result in no binding to Rb were still able to induce phosphorylation of Rb in quiescent BRK cells (47) . Concomitant with Rb phosphorylation was cellular DNA synthesis. This implied that Rb can become phosphorylated in the absence of direct binding to Ela. Perhaps the viral oncoproteins act as a nucleus to reconstitute an active cycin kinase complex that allows the cells to transit through the cell cycle at points where the cell is receiving growth arrest signals.
Each of the DNA tumor virus proteins has now been observed to allow the phosphorylation of Rb under conditions in which Rb is normally underphosphorylated. This implies that the mere binding ofRb is not the only mechanism by which the viral oncoproteins can exert their effect. Binding to Rb may play a role in the action of the viral oncoproteins but this may not be the sole mechanism of action.
